BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs (NASDAQ: BIOA), a clinical-stage biotechnology company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major investor conferences in September 2025.
The company will present at Citi's 2025 Biopharma Back to School Conference in Boston (September 2-3) and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York (September 8-10). CEO Kristen Fortney and CFO Dov Goldstein will conduct fireside chats and one-on-one meetings at both events. Webcasts will be available live and archived for 30 days on the company's investor relations website.
BioAge Labs (NASDAQ: BIOA), societ脿 biotech in fase clinica focalizzata sullo sviluppo di terapie per le malattie metaboliche studiando la biologia dell'invecchiamento, ha annunciato la partecipazione a due importanti conferenze per investitori a settembre 2025.
L'azienda presenter脿 al Citi's 2025 Biopharma Back to School Conference a Boston (2-3 settembre) e al Morgan Stanley 23rd Annual Global Healthcare Conference a New York (8-10 settembre). La CEO Kristen Fortney e il CFO Dov Goldstein terranno fireside chat e incontri one-to-one a entrambi gli eventi. I webcast saranno disponibili in diretta e archiviati per 30 giorni sul sito web investor relations della societ脿.
BioAge Labs (NASDAQ: BIOA), una empresa biotecnol贸gica en fase cl铆nica centrada en desarrollar terapias para enfermedades metab贸licas a partir de la biolog铆a del envejecimiento, ha anunciado su participaci贸n en dos importantes conferencias para inversores en septiembre de 2025.
La compa帽铆a presentar谩 en la Citi's 2025 Biopharma Back to School Conference en Boston (2-3 de septiembre) y en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York (8-10 de septiembre). La CEO Kristen Fortney y el CFO Dov Goldstein ofrecer谩n charlas fireside y reuniones individuales en ambos eventos. Los webcasts estar谩n disponibles en directo y archivados durante 30 d铆as en la web de relaciones con inversores de la compa帽铆a.
BioAge Labs (NASDAQ: BIOA)電� 雲疙檾 靸濍頃欖潉 韱淀暣 雽�靷� 歆堩櫂 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 9鞗� 霊� 瓯挫潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
須岇偓電� 氤挫姢韯挫棎靹� 鞐措Μ電� Citi's 2025 Biopharma Back to School Conference(9鞗� 2鈥�3鞚�)鞕� 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley 23rd Annual Global Healthcare Conference(9鞗� 8鈥�10鞚�)鞐愳劀 氚滍憸頃╇媹雼�. CEO 韥Μ鞀ろ厫 韽姼雼�(Kristen Fortney)鞕� CFO 霃勲笇 瓿摐鞀ろ儉鞚�(Dov Goldstein)鞚� 鞏� 頄夓偓鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘瓿� 1:1 氙疙寘鞚� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼電� 鞁れ嫓臧� 鞀ろ姼毽皪霅橂┌ 須岇偓 韴瀽鞛愱磤瓿� 鞗轨偓鞚错姼鞐� 30鞚缄皠 鞎勳勾鞚措笇搿� 鞝滉车霅╇媹雼�.
BioAge Labs (NASDAQ: BIOA), une soci茅t茅 biotechnologique en phase clinique ax茅e sur le d茅veloppement de traitements des maladies m茅taboliques via la biologie du vieillissement, a annonc茅 sa participation 脿 deux grandes conf茅rences investisseurs en septembre 2025.
La soci茅t茅 pr茅sentera 脿 la Citi's 2025 Biopharma Back to School Conference 脿 Boston (2-3 septembre) et 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference 脿 New York (8-10 septembre). La CEO Kristen Fortney et le CFO Dov Goldstein animeront des discussions fireside et des rencontres individuelles lors des deux 茅v茅nements. Les webcasts seront diffus茅s en direct et archiv茅s pendant 30 jours sur le site relations investisseurs de la soci茅t茅.
BioAge Labs (NASDAQ: BIOA), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapeutika f眉r Stoffwechselerkrankungen 眉ber die Erforschung der Alterungsbiologie konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird auf der Citi's 2025 Biopharma Back to School Conference in Boston (2.鈥�3. September) und der Morgan Stanley 23rd Annual Global Healthcare Conference in New York (8.鈥�10. September) pr盲sentieren. CEO Kristen Fortney und CFO Dov Goldstein werden bei beiden Veranstaltungen Fireside-Chats und Einzelgespr盲che f眉hren. Webcasts sind live verf眉gbar und werden f眉r 30 Tage im Investor-Relations-Bereich der Unternehmenswebsite archiviert.
- None.
- None.
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
- Citi鈥檚 2025 Biopharma Back to School Conference (Boston, September 2鈥�3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 3 at 3:15鈥�3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register .
- Morgan Stanley 23rd Annual Global Healthcare Conference (New York, September 8鈥�10, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 10 at 10:00鈥�10:45 AM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register .
Replays of the webcasts will be available in the investor section of the company's website at , and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge鈥檚 additional preclinical programs, which leverage insights from the Company鈥檚 proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, [email protected]
IR: Dov Goldstein, [email protected]
Partnering: [email protected]
Web: https://bioagelabs.com
FAQ
When is BioAge Labs (BIOA) presenting at the Citi Biopharma Conference 2025?
When is BioAge Labs (BIOA) presenting at the Morgan Stanley Healthcare Conference 2025?
Who will be presenting at the BioAge Labs (BIOA) investor conferences?
How can investors access BioAge Labs (BIOA) conference presentations?
What type of company is BioAge Labs (BIOA)?
